Trovagene (TROV) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TrovaGene (TROV) Commercial Program Underway With A Key Advantage - Piper Jaffray
March 11, 2016 11:02 AM ESTPiper Jaffray analyst, William Quirk, believes Trovagene Inc's (NASDAQ: TROV) collection advantage (~100mL of urine vs. ~10mL of blood) is a competitive advantage that will allow it to take share and eventually approach value based pricing. PT drops $1 to $8 but the Overweight rating remains.
Adjusted EPS of ($0.26) was unfavorable to consensus of ($0.25). Trovagene is making progress on the reimbursement front and now has 150M covered lives. Management reiterated upcoming publications and data presentations as well as expanded panels... More
